The earnings call highlighted significant progress in revenue growth, operational efficiencies, and strategic focus on the LineaRx subsidiary. However, it also outlined challenges such as an increased net loss, a major business segment exit, and ongoing concerns about the company's financial stability. Despite these challenges, the strategic restructuring and new opportunities in the LineaRx segment suggest a cautiously optimistic outlook.

Company Guidance

During the Applied DNA Sciences First Quarter Fiscal 2025 Financial Results call, the company announced several key financial and strategic updates. Total revenues for the first quarter increased to $1.2 million from $891,000 in the same period of fiscal 2024, primarily due to higher product revenue from the DNA tagging business segment and increased textiles isotopic testing services revenue. The company reported an operating loss of $3 million, an improvement from the $3.8 million loss in the prior year, primarily due to lower selling, general, and administrative costs. However, the net loss widened to $2.7 million compared to $1.1 million the previous year, with adjusted EBITDA improving to negative $2.9 million from negative $3.2 million. Cash and cash equivalents as of December 31 totaled $9.3 million, up from $6.4 million at the end of September 2024, reflecting proceeds from an October offering. As part of a strategic restructuring aimed at focusing on its LineaRx subsidiary, Applied DNA announced its exit from the DNA tagging and security products and services business segment and a 20% workforce reduction, with a one-time charge of approximately $300,000 anticipated. The company emphasized LineaRx's growth potential, highlighting its GMP Site One certification and the introduction of new products like Linea Donor DNA for CRISPR applications.

Revenue Growth

Total revenues for the first quarter of fiscal 2025 were $1.2 million, a 34.7% increase compared with $891,000 for the same period of fiscal 2024, driven by higher product revenue.

Operational Efficiency

Operating loss improved to $3 million from $3.8 million in the prior year period due to lower selling, general, and administrative costs.

LineaRx Expansion

LineaRx's customer acquisition rates exceeded expectations with over twenty-five customer projects engaged in fiscal 2024, anticipating multiple projects to enter the clinic in calendar 2025.

GMP Site Certification

Certification of the GMP Site One facility achieved, showcasing a low CapEx approach to enzymatic DNA production at scale.

Strategic Restructuring

Implemented a strategic restructuring to bolster cash reserves and optimize cost structure, with a focus on LineaRx subsidiary.

Applied DNA Sciences (APDN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

APDN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Dec 11, 2025	2025 (Q4)	- / -	-240	―	―	―
Aug 14, 2025	2025 (Q3)	-37.50 / -33.41	352.5	-109.48% (-385.91)	―	―
May 15, 2025	2025 (Q2)	-45.00 / -230.25	-3982.5	94.22% (+3752.25)	―	―
Feb 13, 2025	2025 (Q1)	- / -420.00	-1350	68.89% (+930.00)	―
Dec 17, 2024	2024 (Q4)	-255.00 / -240.00	-3900	93.85% (+3660.00)	―	―
Aug 08, 2024	2024 (Q3)	-371.25 / 352.50	-3600	109.79% (+3952.50)
May 10, 2024	2024 (Q2)	-3375.00 / -3982.50	750	-631.00% (-4732.50)	―	―
Feb 08, 2024	2024 (Q1)	-4650.00 / -1350.00	-4500	70.00% (+3150.00)
Dec 07, 2023	2023 (Q4)	-3975.00 / -3900.00	-1111.575	-250.85% (-2788.43)	―
Aug 10, 2023	2023 (Q3)	-3600.00 / -3600.00	-1950	-84.62% (-1650.00)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

APDN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 14, 2025	$4.07	$3.91	-3.93%
May 15, 2025	$12.15	$10.05	-17.28%
Feb 13, 2025	$130.65	$127.58	-2.35%
Dec 17, 2024	$172.50	$174.67	+1.26%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Applied DNA Sciences (APDN) report earnings?

Applied DNA Sciences (APDN) is schdueled to report earning on Dec 11, 2025, After Close (Confirmed).

What is Applied DNA Sciences (APDN) earnings time?

Applied DNA Sciences (APDN) earnings time is at Dec 11, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is APDN EPS forecast?

Currently, no data Available

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing